Project Grant R35GM155165

Award Date 7/1/24
Completion Date 4/30/29
Dollars Obligated $1.2M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
This Project Grant award of $455,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to decrease sepsis mortality in the pediatric population. The key products and services to be delivered include: Developing an AI-guided early sepsis identification tool to enable timely diagnosis and treatment. Performing sepsis phenotyping and creating digital twin patient models to predict personalized treatment responses....
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $819,166 to Albany Medical College to conduct research on the role of the endothelium in organ dysfunction and failure during critical illnesses like sepsis. The project aims to identify key signaling pathways and transcriptional regulators in endothelial cells that contribute to acute shock, organ damage, and long-term...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $418,750.00 to The Feinstein Institutes for Medical Research to conduct research on T cell receptor-mediated T cell activation in neonatal and pediatric sepsis. The goal is to gain insight into how T cell memory influences sepsis-associated organ dysfunction, by comparing responses between human neonates with sepsis and...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) is funding a research project titled "TARGETING IMMUNE DYSREGULATED ENDOTYPES IN SEPSIS (TIDES)" at The Children's Hospital of Philadelphia (CHOP). The total award amount is $179,475.00 and the project period runs from June 1, 2025 to May 31, 2028. The key objectives of this research project are to: 1) Define and prospectively evaluate...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $473,937 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a novel point-of-care liquid biopsy for early detection of sepsis-associated organ damage. The project aims to optimize a microfluidic enrichment and digital PCR assay to detect tissue-derived circulating rare cells...
This $598,228 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to investigate the role of endoplasmic reticulum autophagy (ER-phagy) in the immune response during sepsis. The research team at the University of Illinois will use state-of-the-art methods to define the mechanisms by which ER-phagy regulates the NLRP3 inflammasome activation and cytokine release in macrophages, ultimately contributing to lung injury during...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of a novel monocyte transcriptional state, termed "monocyte substate 1" (MS1), in the immunopathogenesis and patient heterogeneity of sepsis. The 5-year project will apply single-cell RNA...
This Project Grant award of $186,221 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop personalized sepsis therapeutics for pediatric patients. The key objectives are to: 1) Augment sepsis phenotypes using high-frequency physiologic data to identify additional subtypes and predict disease progression; 2) Retrospectively identify signs of bloodstream infection prior to traditional diagnostic signs...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to unravel the relationships between gut and blood microbial signatures and immune responses in sepsis patients. The $403,750 award to Duke University will support a prospective longitudinal study to integrate gut microbial community profiling, metabolomics, measures of intestinal permeability, and blood microbial signatures with immune...
This $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s IMMUNIX platform, a precision medicine endotyping solution for sepsis. The project aims to: 1) validate the IMMUNOSCAN multiplex rapid test and mapping functions to Luminex immunoassays; 2) validate a parsimonious model for point-of-care endotyping; and 3) demonstrate the ability to...

TRANSLATIONAL APPROACHES TO UNRAVEL ORGAN-SPECIFIC MICROVASCULAR ENDOTHELIAL RESPONSES IN SEPSIS. - TRANSLATIONAL APPROACHES TO UNRAVEL ORGAN-SPECIFIC MICROVASCULAR ENDOTHELIAL RESPONSES IN SEPSIS. PROGRAM SUMMARY: SEPSIS IS DEFINED AS LIFE-THREATENING ORGAN DYSFUNCTION CAUSED BY A DYSREGULATED HOST RESPONSE TO AN INFECTION AND IS ASSOCIATED WITH HIGH MORTALITY. SYSTEMIC INFLAMMATION AND ENDOTHELIAL ACTIVATION WITH RESULTANT MICROVASCULAR LEAK, THROMBOSES, AND HYPOXIC TISSUE INJURY ARE HALLMARKS OF SEPSIS. YET, IN OVER 100 TRIALS, DRUGS AIMED AT MODULATING CASCADES OF INFLAMMATION AND COAGULATION HAVE NOT PROVEN TO BE EFFICACIOUS. THE PRIMARY REASON FOR THIS FAILURE IS ATTRIBUTED TO CLINICAL AND BIOLOGICAL VARIABILITY AMONG CRITICALLY ILL PATIENTS. MORE RECENTLY, HIGH-THROUGHPUT APPROACHES INCLUDING GENE-EXPRESSION PROFILING HAVE SHOWN PROMISE IN DISENTANGLING PATIENT- LEVEL HETEROGENEITY IN THE HOST IMMUNE RESPONSE. IN CONTRAST, SAMPLING CHALLENGES COUPLED WITH CELL AND ORGAN LEVEL HETEROGENEITY HAVE IMPEDED A SIMILAR UNDERSTANDING OF THE HOST ENDOTHELIAL RESPONSE. IT FOLLOWS THAT TRANSLATIONAL APPROACHES THAT SHED LIGHT ON HUMAN MICROVASCULAR PATHOBIOLOGY MAY LEAD TO THE DISCOVERY OF TARGETED THERAPIES THAT RESTORE TISSUE HOMEOSTASIS AND SHIFT SEPSIS CARE PARADIGMS TOWARD ORGAN RECOVERY. MY RESEARCH PROGRAM SEEKS TO ADDRESS KEY KNOWLEDGE GAPS THAT CURRENTLY IMPEDE SCIENTIFIC PROGRESS THROUGH PROJECTS SPANNING 3 DOMAINS. 1) DISCOVERY: THE ENDOTHELIUM IN PATIENTS REMAINS INACCESSIBLE. MOREOVER, WHILE ENDOTHELIAL HETEROGENEITY AND ORGAN-SPECIFICITY ARE INCREASINGLY RECOGNIZED, THEIR CONTRIBUTION TO THE EVOLUTION OF ORGAN DYSFUNCTIONS REMAINS POORLY UNDERSTOOD. TO ADDRESS THIS, WE WILL ENRICH CIRCULATING ENDOTHELIAL CELLS FROM WHOLE BLOOD OF CHILDREN WITH SEPTIC SHOCK WITH THE PRIMARY OBJECTIVE OF DEVELOPING A TRANSCRIPTOMIC ATLAS AT SINGLE-CELL RESOLUTION. BY COMPARING SIGNATURES OF CIRCULATING ENDOTHELIAL SUBSETS FROM PATIENTS, RELATIVE TO PUBLISHED DATASETS OF TISSUE-RESIDENT ENDOTHELIAL CELLS, WE WILL IDENTIFY ORGAN-SPECIFIC TARGETS FOR FUTURE HYPOTHESES TESTING. 2) DISEASE MODELS: THE REDUCTIONIST NATURE OF CURRENT PRECLINICAL MODELS HAS IMPEDED TRANSLATION OF BASIC SCIENCE DISCOVERIES INTO IMPROVED SEPSIS OUTCOMES. THUS, THERE IS A SIGNIFICANT NEED FOR ADVANCED DISEASE MODELS THAT RECAPITULATE HUMAN SEPSIS PATHOBIOLOGY. MY LABORATORY WILL DEVELOP HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED MICROVASCULAR ORGANOIDS AND STIMULATE THEM WITH BIOMARKER RISK- STRATIFIED PLASMA FROM PATIENTS TO MODEL ENDOTHELIAL DYSFUNCTION IN HUMAN SEPSIS. OUR MODELS ARE EXPECTED TO SERVE AS ROBUST TESTBEDS FOR HYPOTHESES TESTING. 3) DISEASE MECHANISMS: FINALLY, WE WILL ESTABLISH CUTTING- EDGE CRISPR-CAS9 GENE-EDITING TOOLS IN VITRO TO EFFICIENTLY STUDY THE MECHANISTIC BASIS OF CANDIDATE GENES IDENTIFIED THROUGH OUR STUDIES. THIS TRANSDISCIPLINARY PROPOSAL IS MADE FEASIBLE BY A LONG-STANDING STUDY OF PEDIATRIC SEPTIC SHOCK WITH UNPARALLELED ACCESS TO BIOSPECIMENS, INSTITUTIONAL SHARED RESOURCES, AND ONGOING COLLABORATIONS WITH A RICH NETWORK OF SCIENTISTS WITH TECHNICAL EXPERTISE. THE APPROACHES ESTABLISHED THROUGH THIS PROPOSAL ARE EXPECTED TO ENHANCE OUR UNDERSTANDING OF ORGAN-SPECIFIC MICROVASCULAR ENDOTHELIAL RESPONSES AND HOLD POTENTIAL TO INFORM DEVELOPMENT OF PRECISION THERAPIES. FUNDING THROUGH THE NIGMS ESI- MIRA WILL THUS MAXIMIZE MY LABORATORY'S RESEARCH EFFORTS TO IMPROVE THE OUTCOMES OF CHILDREN WITH SEPSIS.

Posted 6/13/24